Skip to main content
SpringerLink
Log in

Elevated Serum Ghrelin Exerts an Orexigenic Effect that May Maintain Body Mass Index in Patients with Metastatic Neuroendocrine Tumors

  • Published:
Journal of Molecular Neuroscience Aims and scope Submit manuscript

Abstract

Ghrelin is a potent orexigenic peptide principally produced in the stomach by a distinct population of neuroendocrine cells in the oxyntic mucosa of the fundus. Exogenous ghrelin given as an intravenous infusion has been shown to increase caloric intake in patients with cancer cachexia. In this study, we hypothesized that elevated endogenous ghrelin, produced by increased neuroendocrine cell tumor burden, also exerts an orexigenic effect helping to maintain body mass index. To evaluate the effect of elevated endogenous ghrelin, 35 patients with neuroendocrine tumors were enrolled, assigning them to one of two groups depending on the presence of hepatic metastases. Following an overnight fast, serum was collected and sent for ghrelin measurement by an outside laboratory. The two groups were well matched for all other relevant clinical variables including subtype of tumor, primary location of tumor and tumor treatment history. Nearly all patients with hepatic metastases had elevated levels of ghrelin compared to the standard reference range given for matched controls. The presence of hepatic metastases was associated with significantly elevated ghrelin levels (p<0.05) and a greater mean body mass index. In addition, we report a positive correlation between serum ghrelin and total tumor surface area and between serum ghrelin and body mass index, suggesting that elevated endogenous ghrelin may be sufficient to overcome any partial ghrelin resistance typically seen in cancer cachexia. These results support the possibility that ghrelin is co-released from neuroendocrine tumors and exerts an orexigenic effect in these patients, helping to maintain their body mass index despite widely disseminated disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Abou-Saif, A., Gibril, F., Ojeaburu, J. V., Bashir, S., Entsuah, L. K., Asgharian, B., et al. (2003). Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer, 98, 249–261.

    Article  PubMed  CAS  Google Scholar 

  • Akamizu, T., Takaya, K., Irako, T., Hosoda, H., Teramukai, S., Matsuyama, A., et al. (2004). Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. European Journal of Endocrinology, 150, 447–455.

    Article  PubMed  CAS  Google Scholar 

  • Aparicio, T., Ducreux, M., Baudin, E., Sabourin, J. C., De Baere, T., Mitry, E., et al. (2001). Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. European Journal of Cancer, 37, 1014–1019.

    Article  PubMed  CAS  Google Scholar 

  • Bordi, C., D'Adda, T., Azzoni, C., Pilato, F. P., & Caruana, P. (1995). Hypergastrinemia and gastric enterochromaffin-like cells. American Journal of Surgical Pathology, 19, S8–S19.

    PubMed  Google Scholar 

  • Broglio, F., Gottero, C., Prodam, F., Gauna, C., Muccioli, G., Papotti, M., et al. (2004). Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. Journal of Clinical Endocrinology and Metabolism, 89, 3062–3065.

    Article  PubMed  CAS  Google Scholar 

  • Corbetta, S., Peracchi, M., Cappiello, V., Lania, A., Lauri, E., Vago, L., et al. (2003). Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: Identification of one pancreatic ghrelinoma. Journal of Clinical Endocrinology and Metabolism, 88, 3117–3120.

    Article  PubMed  CAS  Google Scholar 

  • Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., et al. (2002). Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. New England Journal of Medicine, 346, 1623–1630.

    Article  PubMed  Google Scholar 

  • Date, Y., Kojima, M., Hosoda, H., Sawaguchi, A., Mondal, M. S., Suganuma, T., et al. (2000). Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology, 141, 4255–4261.

    Article  PubMed  CAS  Google Scholar 

  • Dornonville de la Cour, C., Bjorkqvist, M., Sandvik, A. K., Bakke, I., Zhao, C. M., Chen, D., et al. (2001). A-like cells in the rat stomach contain ghrelin and do not operate under gastrin control. Regulatory Peptides, 99, 141–150.

    Article  PubMed  CAS  Google Scholar 

  • Ducreux, M., Ruszniewski, P., Chayvialle, J. A., Blumberg, J., Cloarec, D., Michel, H., et al. (2000). The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. American Journal of Gastroenterology, 95, 3276–3281.

    Article  PubMed  CAS  Google Scholar 

  • Freda, P. U., Reyes, C. M., Conwell, I. M., Sundeen, R. E., & Wardlaw, S. L. (2003). Serum ghrelin levels in acromegaly: Effects of surgical and long-acting octreotide therapy. Journal of Clinical Endocrinology and Metabolism, 88, 2037–2044.

    Article  PubMed  CAS  Google Scholar 

  • Fykse, V., Sandvik, A. K., Qvigstad, G., Falkmer, S. E., Syversen, U., & Waldum, H. L. (2004). Treatment of ECL cell carcinoids with octreotide LAR. Scandinavian Journal of Gastroenterology, 39, 621–628.

    Article  PubMed  CAS  Google Scholar 

  • Garcia, J. M., Garcia-Touza, M., Hijazi, R. A., Taffet, G., Epner, D., Mann, D., et al. (2005). Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. Journal of Clinical Endocrinology and Metabolism, 90, 2920–2926.

    Article  PubMed  CAS  Google Scholar 

  • Hanada, T., Toshinai, K., Kajimura, N., Nara-Ashizawa, N., Tsukada, T., Hayashi, Y., et al. (2003). Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochemical and Biophysical Research Communications, 301, 275–279.

    Article  PubMed  CAS  Google Scholar 

  • Haqq, A. M., Stadler, D. D., Rosenfeld, R. G., Pratt, K. L., Weigle, D. S., Frayo, R. S., et al. (2003). Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader–Willi syndrome. Journal of Clinical Endocrinology and Metabolism, 88, 3573–3576.

    Article  PubMed  CAS  Google Scholar 

  • Imtiaz, K. E., Monteith, P., & Khaleeli, A. (2000). Complete histological regression of metastatic carcinoid tumour after treatment with octreotide. Clinica Endocrinologica, 53, 755–758.

    Article  CAS  Google Scholar 

  • Inui, A., Asakawa, A., Bowers, C. Y., Mantovani, G., Laviano, A., Meguid, M. M., et al. (2004). Ghrelin, appetite, and gastric motility: The emerging role of the stomach as an endocrine organ. FASEB Journal, 18, 439–456.

    Article  PubMed  CAS  Google Scholar 

  • Kojima, M. & Kangawa, K. (2005) Ghrelin: Structure and function. Physiological Reviews, 85, 495–522.

    Article  PubMed  CAS  Google Scholar 

  • Neary, N. M., Small, C. J., Wren, A. M., Lee, J. L., Druce, M. R., Palmieri, C., et al. (2004). Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism, 89, 2832–2836.

    Article  PubMed  CAS  Google Scholar 

  • Papotti, M., Cassoni, P., Volante, M., Deghenghi, R., Muccioli, G., & Ghigo, E. (2001). Ghrelin-producing endocrine tumors of the stomach and intestine. Journal of Clinical Endocrinology and Metabolism, 86, 5052–5059.

    Article  PubMed  CAS  Google Scholar 

  • Popovic, V., Miljic, D., Pekic, S., Pesko, P., Djurovic, M., Doknic, M., et al. (2005). Low plasma ghrelin level in gastrectomized patients is accompanied by enhanced sensitivity to the ghrelin-induced growth hormone release. Journal of Clinical Endocrinology and Metabolism, 90, 2187–2191.

    Article  PubMed  CAS  Google Scholar 

  • Ramos, E. J., Suzuki, S., Marks, D., Inui, A., Asakawa, A., & Meguid, M. M. (2004). Cancer anorexia–cachexia syndrome: Cytokines and neuropeptides. Current Opinion in Clinical Nutrition and Metabolic Care, 7, 427–434.

    Article  PubMed  CAS  Google Scholar 

  • Rindi, G., Savio, A., Torsello, A., Zoli, M., Locatelli, V., Cocchi, D., et al. (2002). Ghrelin expression in gut endocrine growths. Histochemistry and Cell Biology, 117, 521–525.

    Article  PubMed  CAS  Google Scholar 

  • Rigamonti, A. E., Pincelli, A. I., Corra, B., Viarengo, R., Bonomo, S. M., Galimberti, D., et al. (2002). Plasma ghrelin concentrations in elderly subjects: Comparison with anorexic and obese patients. Journal of Endocrinology, 175, R1–R5.

    Article  PubMed  CAS  Google Scholar 

  • Shiiya, T., Nakazato, M., Mizuta, M., Date, Y., Mondal, M. S., Tanaka, M., et al. (2002). Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. Journal of Clinical Endocrinology and Metabolism, 87, 240–244.

    Article  PubMed  CAS  Google Scholar 

  • Shimada, M., Date, Y., Mondal, M. S., Toshinai, K., Shimbara, T., Fukunaga, K., et al. (2003). Somatostatin suppresses ghrelin secretion from the rat stomach. Biochemical and Biophysical Research Communications, 302, 520–525.

    Article  PubMed  CAS  Google Scholar 

  • Shimizu, Y., Nagaya, N., Isobe, T., Imazu, M., Okumura, H., Hosoda, H., et al. (2003). Increased plasma ghrelin level in lung cancer cachexia. Clinical Cancer Research, 9, 774–778.

    PubMed  CAS  Google Scholar 

  • Silva, A. P., Bethmann, K., Raulf, F., & Schmid, H. A. (2005). Regulation of ghrelin secretion by somatostatin analogs in rats. European Journal of Endocrinology, 152, 887–894.

    Article  PubMed  CAS  Google Scholar 

  • Srivastava, A., Kamath, A., Barry, S. A., & Dayal, Y. (2004). Ghrelin expression in hyperplastic and neoplastic proliferations of the enterochromaffin-like (ECL) cells. Endocrine Pathology, 15, 47–54.

    Article  PubMed  CAS  Google Scholar 

  • Thompson, G. B., van Heerden, J. A., Martin Jr., J. K., Schutt, A. J., Ilstrup, D. M., & Carney, J. A. (1985). Carcinoid tumors of the gastrointestinal tract: Presentation, management, and prognosis. Surgery, 98, 1054–1063.

    PubMed  CAS  Google Scholar 

  • Tschop, M., Weyer, C., Tataranni, P. A., Devanarayan, V., Ravussin, E., & Heiman, M. L. (2001). Circulating ghrelin levels are decreased in human obesity. Diabetes, 50, 707–709.

    Article  PubMed  CAS  Google Scholar 

  • Tsolakis, A. V., Portela-Gomes, G. M., Stridsberg, M., Grimelius, L., Sundin, A., Eriksson, B. K., et al. (2004). Malignant gastric ghrelinoma with hyperghrelinemia. Journal of Clinical Endocrinology and Metabolism, 89, 3739–3744.

    Article  PubMed  CAS  Google Scholar 

  • Volante, M., Allia, E., Gugliotta, P., Funaro, A., Broglio, F., Deghenghi, R., et al. (2002). Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. Journal of Clinical Endocrinology and Metabolism, 87, 1300–1308.

    Article  PubMed  CAS  Google Scholar 

  • Wierup, N., Svensson, H., Mulder, H., & Sundler, F. (2002). The ghrelin cell: A novel developmentally regulated islet cell in the human pancreas. Regulatory Peptides, 107, 63–69.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

Supported by a Department of Veteran Affairs Merit Review Grant (JRP).

Author information

Authors and Affiliations

  1. Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    Hank S. Wang, David S. Oh, Gordon V. Ohning & Joseph R. Pisegna

  2. Division of Gastroenterology and Hepatology, VA Greater Los Angeles Healthcare System, Building 115, Room 316, 11301 Wilshire Blvd., Los Angeles, CA, 90073, USA

    David S. Oh, Gordon V. Ohning & Joseph R. Pisegna

Authors
  1. Hank S. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David S. Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gordon V. Ohning
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joseph R. Pisegna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph R. Pisegna.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, H.S., Oh, D.S., Ohning, G.V. et al. Elevated Serum Ghrelin Exerts an Orexigenic Effect that May Maintain Body Mass Index in Patients with Metastatic Neuroendocrine Tumors. J Mol Neurosci 33, 225–231 (2007). https://doi.org/10.1007/s12031-007-0004-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12031-007-0004-9

Keywords

Search

Navigation